View of Cost-effectiveness analysis of daratumumab, bortezomib, and dexamethasone combination in comparison to carfilzomib, elotuzumab and ixazomib-based therapies for the treatment of patients with relapsed and refractory multiple myeloma from a Brazilian pr

Return to Article Details Cost-effectiveness analysis of daratumumab, bortezomib, and dexamethasone combination in comparison to carfilzomib, elotuzumab and ixazomib-based therapies for the treatment of patients with relapsed and refractory multiple myeloma from a Brazilian pr Download Download PDF